Gary Patou Sells 1,322 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Gary Patou sold 1,322 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the sale, the director owned 24,896 shares in the company, valued at approximately $1,322,973.44. This represents a 5.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Xenon Pharmaceuticals Trading Up 3.1%

Xenon Pharmaceuticals stock opened at $52.79 on Wednesday. Xenon Pharmaceuticals Inc. has a 12 month low of $30.00 and a 12 month high of $63.95. The stock’s 50 day simple moving average is $55.71 and its two-hundred day simple moving average is $48.77. The firm has a market cap of $5.10 billion, a PE ratio of -11.23 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, hitting the consensus estimate of ($1.17). During the same period in the previous year, the business posted ($0.83) earnings per share. On average, equities research analysts forecast that Xenon Pharmaceuticals Inc. will post -4.92 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Kestra Advisory Services LLC acquired a new position in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $33,000. Blue Trust Inc. raised its stake in shares of Xenon Pharmaceuticals by 2,560.7% during the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 717 shares during the period. Danske Bank A S acquired a new position in shares of Xenon Pharmaceuticals during the 3rd quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $43,000. Finally, Aster Capital Management DIFC Ltd acquired a new position in Xenon Pharmaceuticals in the 3rd quarter valued at $39,000. 95.45% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. Needham & Company LLC lowered their price objective on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Wolfe Research assumed coverage on Xenon Pharmaceuticals in a research report on Monday, February 23rd. They issued an “outperform” rating and a $60.00 price objective on the stock. Wedbush lowered their price objective on Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating on the stock in a research report on Monday, March 16th. Stifel Nicolaus set a $66.00 target price on Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Finally, HC Wainwright upped their target price on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $77.20.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.